2. Academic Validation
  3. Simvastatin ameliorates adverse pregnancy by inhibiting glycolysis-related NETs in obstetrical antiphospholipid syndrome

Simvastatin ameliorates adverse pregnancy by inhibiting glycolysis-related NETs in obstetrical antiphospholipid syndrome

  • Life Sci. 2024 Dec 15:359:123215. doi: 10.1016/j.lfs.2024.123215.
Ruiheng Huo 1,  Qipeng Sun 2,  Qingfeng Lv 1,  Yuan Wang 3,  Weiyi Qi 3,  Meihua Zhang 4,  Lei Li 5,  Xietong Wang 6
Affiliations

Affiliations

  • 1 Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China; Laboratory of Medical Science and Technology Innovation Center (Institute of Translational Medicine), Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan, People's Republic of China.
  • 2 School of Clinical and Basic Medicine (Institute of Basic Medicine), Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan, People's Republic of China.
  • 3 Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.
  • 4 Key Laboratory of Birth Regulation and Control Technology of National Health Commission of China, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, People's Republic of China.
  • 5 Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China; Laboratory of Medical Science and Technology Innovation Center (Institute of Translational Medicine), Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan, People's Republic of China. Electronic address: lilei@sdfmu.edu.cn.
  • 6 Department of Obstetrics and Gynaecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China; Laboratory of Medical Science and Technology Innovation Center (Institute of Translational Medicine), Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan, People's Republic of China; School of Clinical and Basic Medicine (Institute of Basic Medicine), Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan, People's Republic of China; Key Laboratory of Birth Regulation and Control Technology of National Health Commission of China, Shandong Provincial Maternal and Child Health Care Hospital, Jinan, People's Republic of China. Electronic address: wxt65@sdfmu.edu.cn.
PMID: 39505298 DOI: 10.1016/j.lfs.2024.123215
Abstract

Aims: Some patients with Obstetric Antiphospholipid Syndrome (OAPS) still experience miscarriage and placental dysfunction after routine treatment, which is related to an abnormal increase in neutrophil extracellular traps (NETs). The labeling of statins has been revised to remove the contraindication for use during pregnancy. Our aim is to investigate the effect of Simvastatin on pregnancy outcomes in OAPS and its correlation mechanisms with NETs.

Main methods: The effect of Simvastatin on pregnancy outcomes was observed. The effect of simvastatin on the function and Apoptosis of neutrophils has evaluated. The effect of Simvastatin to NETs and the changes in oxidative stress levels were observed. Different groups of NETs were extracted to intervene the HTR8-Svneo.RNA-seq analysis of the mechanism of which Simvastatin reduces NETs. Seahorse experiment detected the effect of Simvastatin on neutrophil glycolysis levels. Fluorescence co-localization and flow cytometry and Co-IP were used to verify relevant mechanisms.

Key findings: In the OAPS mice, Simvastatin can reduce embryo absorption rate, reshape placental blood flow perfusion. Simultaneously reducing the production of NETs both in vivo and vitro, remolding oxidative stress. Simvastatin can improve neutrophil dysfunction caused by aPL-IgG. The reduction of NETs improved HTR8-Svneo's dysfunction. The intervention of Simvastatin on neutrophils under the stimulation of aPL-IgG showed a signature in glycolytic. The key rate limiting Enzyme PKM2 in glycolysis interacts with Cit-H2b and PI3K/Akt signaling pathway.

Significance: Our study providing basic theoretical support for the treatment of OAPS with Simvastatin.

Keywords

Neutrophil extracellular trap; Obstetric antiphospholipid syndrome; Oxidative stress; PI3K-AKT-PKM2-glycolysis; Simvastatin.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z